Product Description
INVAC-1 is a DNA plasmid encoding a modified human telomerase reverse transcriptase (hTERT) protein devoid of catalytic activity. (Sourced from: https://aacrjournals.org/clincancerres/article/26/3/588/83062/A-First-in-Human-Phase-I-Study-of-INVAC-1-an)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Invectys
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia
Phase 1: Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04515043 |
NCT02301754 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2020-12-19 |
50% |
2021-06-02 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT02301754 |
INVAC1-CT-101 | P1 |
Completed |
Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified |
2018-02-01 |
41% |
2019-03-20 |
Study Completion Date|Treatments|Trial Status |
NCT03265717 |
INVAC1-CT-201 | P2 |
Terminated |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
2020-06-30 |
31% |
2020-07-12 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |